Key result
Metoprolol increased N-ANF compared to xamoterol at 3 months in patients with heart failure after acute myocardial infarction.
Why the study?
Does metoprolol compared to xamoterol affect neurohormonal activation in patients with heart failure after acute myocardial infarction?
RCT (n=141)
Double-blind
randomized
Does metoprolol compared to xamoterol affect neurohormonal activation in patients with heart failure after acute myocardial infarction?
Metoprolol and xamoterol both decrease sympathetic and renin-angiotensin activity at 3 months in post-MI heart failure, but have divergent effects on N-ANF levels.
Answers are grounded in this paper and cite their sources.
Highlights divergent neurohormonal effects of beta-blockers despite similar RAAS suppression; extends class-heterogeneity evidence in post-MI HF.
BACKGROUND: Few studies have described how neurohormonal activation is influenced by treatment with beta-receptor antagonists in patients with heart failure after acute myocardial infarction. The aims were to describe neurohormonal activity in relation to other variables and to investigate treatment effects of a beta(1) receptor-antagonist compared to a partial beta(1) receptor-agonist. METHODS: Double-blind, randomized comparison of metoprolol 50-100 mg b.i.d. (n=74), and xamoterol 100-200 mg b.i.d (n=67). Catecholamines, neuropeptide Y-like immunoreactivity (NPY-LI), renin activity, and N-terminal pro-atrial natriuretic factor (N-ANF) were measured in venous plasma before discharge and after 3 months. Clinical and echocardiographic variables were assessed. RESULTS: N-ANF showed the closest correlations to clinical and echocardiographic measures of heart failure severity, e.g. NYHA functional class, furosemide dose, exercise tolerance, systolic and diastolic function. Plasma norepinephrine, dopamine and renin activity decreased after 3 months on both treatments, in contrast to a small increase in NPY-LI which was greater (by 3.9 pmol/l, 95% CI 1.2-6.6) in the metoprolol group. N-ANF increased on metoprolol, and decreased on xamoterol (difference: 408 pmol/l, 95% CI 209-607). Increase above median of NPY-LI (>25.2 pmol/l, odds ratio 2.8, P=0.0050) and N-ANF (>1043 pmol/l, odds ratio 2.8, P=0.0055) were related to long term (mean follow-up 6.8 years) cardiovascular mortality. CONCLUSIONS: Decreased neurohormonal activity, reflecting both the sympathetic nervous system and the renin-angiotensin system, was found 3 months after an acute myocardial infarction with heart failure treated with beta-receptor antagonists. The small increase in NPY-LI may suggest increased sympathetic activity or reduced clearance from plasma. The observed changes of N-ANF may be explained by changes in cardiac preload, renal function, and differences in beta-receptor mediated inhibition of atrial release of N-ANF. NPY-LI, and N-ANF at discharge were related to long term cardiovascular mortality.
No takes yet. Share an insight, caveat, or question.
Persson et al. (2002) conducted an RCT in Heart failure after acute myocardial infarction (n=141). Metoprolol vs. Xamoterol 100-200 mg b.i.d. was evaluated on Change in N-terminal pro-atrial natriuretic factor (N-ANF) at 3 months (Difference 408 pmol/l, 95% CI 209-607). Metoprolol increased N-ANF compared to xamoterol at 3 months in patients with heart failure after acute myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: